Search results for "polycystic ovary syndrome"

showing 10 items of 126 documents

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

2015

PURPOSE: Insulin resistance and compensatory hyperinsulinism are the predominant metabolic defects in polycystic ovary syndrome (PCOS). However, hyperinsulinism, as well as being compensatory, can also express a condition of reduced insulin clearance. Our aim was to evaluate the differences in insulin action and metabolism between women with PCOS (with normal glucose tolerance) and age- and BMI-matched women with prediabetes (without hyperandrogenism and ovulatory disorders). METHODS: 22 women with PCOS and 21 age/BMI-matched women with prediabetes were subjected to a Hyperinsulinemic-euglycemic clamp and an Oral Glucose tolerance Test (OGTT). Insulin sensitivity was assessed by the glucose…

Adultmedicine.medical_specialtyendocrine system diseasesAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/13 - EndocrinologiaPrediabetic StateYoung AdultEndocrinologyInsulin resistanceInternal medicineHyperinsulinismmedicineHumansInsulinPrediabetesbusiness.industryPolycystic ovary syndrome (PCOS)InsulinHyperandrogenismnutritional and metabolic diseasesGlucose clamp techniquemedicine.diseasePolycystic ovaryEndocrinologypolycystic ovary syndromeGlucose Clamp TechniqueFemaleInsulin ResistancebusinessHyperinsulinismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes

2007

Background: Serum DHEAS has been found to be elevated in some women with polycystic ovary syndrome (PCOS). We wished to determine whether this prevalence is different in women with androgen excess who have different phenotypes and to correlate these findings with various cardiovascular and metabolic parameters. Methods: Two hundred and thirty-eight young hyperandrogenic women categorized into various diagnostic groups were evaluated for elevations in serum DHEAS, testosterone, glucose, insulin, quantitative insulin-sensitivity check index (QUICKI), cholesterol, HDL-C, LDL-C, triglycerides and C-reactive protein (CRP). Data were stratified based on elevations in DHEAS. Results: Serum DHEAS w…

Adultmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAndrogen Excesschemistry.chemical_compoundEndocrinologyInternal medicinePrevalenceHumansInsulinMedicineTestosteroneTestosteronebusiness.industryCholesterolInsulinPolycystic ovary syndrome (PCOS)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePhenotypePolycystic ovaryPhenotypeEndocrinologychemistryAdrenal CortexAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance.

2015

ObjectiveOxidative stress and mitochondrial dysfunction are implicated in polycystic ovary syndrome (PCOS). The present study assesses the effect of metformin treatment on mitochondrial function in polymorphonuclear cells from PCOS subjects. Additionally, we evaluate endocrine parameters and levels of interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα).Design and methodsOur study population was comprised of 35 women of reproductive age diagnosed with PCOS and treated with metformin for 12 weeks, and their corresponding controls (n=41), adjusted by age and BMI. We evaluated the alteration of endocrinological and anthropometrical parameters and androgen levels. Mitochondrial O2 consum…

Adultmedicine.medical_specialtyendocrine system diseasesNeutrophilsEndocrinology Diabetes and MetabolismMitochondrionBiologymedicine.disease_causechemistry.chemical_compoundYoung AdultEndocrinologyDehydroepiandrosterone sulfateInsulin resistanceInternal medicinemedicineHumansHypoglycemic Agentschemistry.chemical_classificationReactive oxygen speciesInterleukin-6Tumor Necrosis Factor-alphanutritional and metabolic diseasesGeneral MedicineGlutathionemedicine.diseasePolycystic ovaryMetforminMetforminMitochondriaEndocrinologyTreatment OutcomechemistryFemaleInsulin ResistanceOxidative stressmedicine.drugPolycystic Ovary Syndrome
researchProduct

Uterine effects of metformin administration in anovulatory women with polycystic ovary sindrome

2006

Background Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whil…

Adultmedicine.medical_specialtyendocrine system diseasesPhysiologymedia_common.quotation_subjectUterusEndometriumFertility AgentsAnovulationEndometriumanovulation; endometrium; metforminMenstruation-Inducing AgentUltrasoundmedicinePCOSHumansOvulationFertility Agentmedia_commonGynecologyMenstruation-Inducing Agentsbusiness.industryRehabilitationUterusanovulation endometrium metformin PCOS ultrasoundnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsMetforminMetforminPregnancy ratemedicine.anatomical_structureUteruReproductive MedicineIn uteroRegional Blood FlowFemalebusinessmedicine.drugAnovulationHumanPolycystic Ovary SyndromeDevelopmental Biology
researchProduct

Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?

2018

For some time, it has been assumed that women with polycystic ovary syndrome (PCOS) are at increased risk of developing cardiovascular disease (CVD). This has largely been on the basis of having many risk factors, including abnormal lipid profile, insulin resistance, and markers of inflammation. However, despite having these and other risk factors, we argue here, in the view of the authors, that there is no credible evidence that there is greater CVD morbidity in all women with PCOS. We analyze the existing data and discuss that overall CVD risk decreases with age when more CVD events are likely to occur, and introduce the possibility that there may be some unknown inherent protective facto…

Adultmedicine.medical_specialtyendocrine system diseasesProtective factor030209 endocrinology & metabolismDiseaseRisk Assessment03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsDiabetes mellitusmedicineDiabetes MellitusHumansObesityMenstruation Disturbances030219 obstetrics & reproductive medicinebusiness.industryObstetricsHyperandrogenismAbsolute risk reductionnutritional and metabolic diseasesGeneral Medicinemedicine.diseasePolycystic ovaryObesityfemale genital diseases and pregnancy complicationsCardiovascular DiseasesFemalebusinessHyperandrogenismRisk Reduction BehaviorPolycystic Ovary SyndromeJournal of women's health (2002)
researchProduct

Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression

2019

Abstract Background A limited number of publications have assessed the prevalence of hypertension (HTN) in polycystic ovary syndrome (PCOS) patients with inconclusive results. Since in general populations the occurrence of hypertension is related to age per se, we investigated the prevalence (P) / relative risk (RR) of HTN in pooled patients with PCOS, vs control population among reproductive age women with PCOS, compared to menopause/aging patients. Methods PubMed, Scopus, ScienceDirect, web of science, and Google scholar were systematically searched for retrieving observational studies published from inception to April 2019 investigating the HTN in patients with PCOS. The primary outcome …

Adultmedicine.medical_specialtylcsh:QH471-489endocrine system diseasesPopulationReproductive medicineComorbidityReview:Medisinske Fag: 700::Klinisk medisinske fag: 750::Endokrinologi: 774 [VDP]lcsh:Gynecology and obstetricsRisk AssessmentEndocrinologyRisk FactorsInternal medicinemedicinePrevalencelcsh:ReproductionHumansMeta-regressioncardiovascular diseaseseducationlcsh:RG1-991Polycystic ovary syndromeeducation.field_of_studybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsMenopauseRelative riskMeta-analysisReproductive MedicineMeta-analysisRelative riskHypertensionObservational studyFemalebusinessDevelopmental Biology
researchProduct

Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study

2006

Background Previous data on the efficacy of clomiphene citrate, the most commonly used drug for treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS), have shown a discrepancy between ovulation and pregnancy rates. In the present subanalysis (of a larger previously published randomized controlled trial), the effect of clomiphene citrate on several ultrasonographic markers of uterine receptivity in PCOS patients who ovulated under treatment was studied. Methods Thirty-three PCOS women who ovulated under 150 mg daily clomiphene citrate and 33 healthy controls were studied. Uterine, subendometrial and endometrial blood flows, endometrial thickness and pattern were …

Adultmedicine.medical_specialtymedia_common.quotation_subjectEarly Pregnancy LossUterusanovulation; clomiphene citrate; Doppler; PCOS; velocimetryBiologyClomiphenelaw.inventionAnovulationRandomized controlled trialPregnancyReference ValueslawClomifeneclomiphene citratemedicinePCOSHumansOvulationUltrasonographymedia_commonGynecologyPregnancyvelocimetryObstetricsRehabilitationEstrogen AntagonistsPregnancy OutcomeDopplerObstetrics and GynecologyGenitalia Femalemedicine.diseasePolycystic ovaryTreatment Outcomemedicine.anatomical_structureReproductive Medicinepolycystic ovary syndromeanovulationFemalemedicine.drug
researchProduct

No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.

2013

Context: Women with type 1 diabetes mellitus (DM1) have a higher prevalence of polycystic ovary syndrome (PCOS) than the general population. Objective: The aim of this study was to clarify, in DM1 women with PCOS(PCOS-DM1), the influence of insulin therapy and glycemic control and evaluate the hormonal and phenotypic differences with age-matched and body mass index (BMI)-matched women with PCOS without diabetes. Design, Setting, and Patients: We evaluated 103 DM1 women with and without PCOS treated with intensive insulin therapy; 38 age-matched and BMI-matched women with PCOS without diabetes were compared in a cross-sectional study. Outcome Measurements: Clinical, anthropometric, and metab…

Adultmusculoskeletal diseasesPCOS Type 1 Diabetescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectClinical BiochemistryPopulationContext (language use)BiochemistryBody Mass IndexSettore MED/13 - EndocrinologiaYoung AdultEndocrinologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationReproductive HistoryMenstrual cyclemedia_commoneducation.field_of_studyType 1 diabetesbusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)nutritional and metabolic diseasesmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsCross-Sectional StudiesDiabetes Mellitus Type 1PhenotypeEndocrinologyCase-Control StudiesFemalebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Mullarian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin-B

2005

Objective: To investigate Müllerian-inhibiting substance (MIS) levels in women with polycystic ovary syndrome (PCOS), as well as relationships to ovarian morphology, levels of inhibin B, and other reproductive hormones. Design: Prospective clinical study. Setting: Academic endocrinology centers in Palermo, Italy and New York. Patient(s): Forty-six women with PCOS, recruited on the basis of the classic criteria of chronic anovulation and hyperandrogenism, and 25 age-matched ovulatory controls. Intervention(s): Fasting blood was obtained in all subjects in the early follicular phase (days 5–6) after spontaneous or induced menses (in PCOS), and transvaginal ultrasounds were performed. Main Out…

Anti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentAnovulationPCOS MIS inhibin B ovarian volume insulinInternal medicinemedicineHumansInsulinInhibinsObesityProspective StudiesAndrostenedioneTestosteroneGlycoproteinsUltrasonographybusiness.industryInsulinOvaryHyperandrogenismObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsTesticular HormonesEndocrinologyFollicular PhaseReproductive MedicineFemalebusinessLuteinizing hormoneBody mass indexBiomarkersAnovulationPolycystic Ovary Syndrome
researchProduct

Heterogenous forms of dyslipidemiain women with polycystic ovary syndrome

2008

Forms of dyslipidemia are very common in individuals affected by polycystic ovary syndrome (PCOS), but in addition to plasmatic lipids, it is necessary to evaluate the alterations in the atherogenic lipoproteins (Lp) and apolipoproteins (apo). In our study we measured the concentrations of apoB, Lp(a) and low density lipoproteins (LDL) in 42 patients with PCOS (age: 28 +/- 7 years, body mass index: 27 +/- 5 kg/m-) and 37 healthy women (of the same age and body mass index). Methods: values of Lp(a) >30 mg/dl were considered high, whereas for apoB, values >100 g/l were considered high. Results: the patients with PCOS showed an increase in triglycerides (p=0.0011) and low levels of high densit…

Atherogenic lipoproteinSettore MED/18 - Chirurgia GeneraleMedicine (all)Body mass indexPolycystic ovary syndrome
researchProduct